PURPOSE: To evaluate the efficacy, predictability, stability, and complications after implantation of a foldable iris-fixated toric phakic intraocular lens (pIOL) to correct myopic astigmatism. SETTING: University Eye Clinic, Paracelsus Medical University, Salzburg, Austria. DESIGN: Retrospective nonrandomized observational case series. METHODS: The study assessed eyes having implantation of an Artiflex toric pIOL with spherical power ranging from -1.0 to -13.5 diopters (D) and additional cylinder from -1.0 to -5.0 D, both in 0.5 D increments. The main parameters were uncorrected (UDVA) and corrected (CDVA) distance visual acuities, manifest refraction stability, slitlamp biomicroscopy, tonometry, and central endothelial cell count (ECC). RESULTS: The study enrolled 42 eyes of 24 patients with a mean age of 35 years (range 18 to 52 years), a mean spherical equivalent of -7.52 D ± 2.22 (SD) (range -2.63 to -13.0 D), and a mean preoperative cylinder of -1.82 ± 0.96 D (range -1.0 to -5.0 D). Six months postoperatively, the UDVA (Snellen lines) was 1.0 or better in 38 eyes (90%). The CDVA improved by 1 line in 22 eyes (52%) and by 2 lines in 2 eyes (5%); no eye lost lines. All eyes were within ±0.50 of the target refraction (spherical equivalent); the mean refractive astigmatism was -0.18 ± 0.30 D. Refraction was stable from 1 day postoperatively. A slight ECC loss (-0.72%) occurred at 6 months. There were no serious complications. CONCLUSION: After a short-time follow-up, toric pIOL implantation was effective, predictable, stable, and safe for the correction of myopic astigmatism.
PURPOSE: To evaluate the efficacy, predictability, stability, and complications after implantation of a foldable iris-fixated toric phakic intraocular lens (pIOL) to correct myopic astigmatism. SETTING: University Eye Clinic, Paracelsus Medical University, Salzburg, Austria. DESIGN: Retrospective nonrandomized observational case series. METHODS: The study assessed eyes having implantation of an Artiflex toric pIOL with spherical power ranging from -1.0 to -13.5 diopters (D) and additional cylinder from -1.0 to -5.0 D, both in 0.5 D increments. The main parameters were uncorrected (UDVA) and corrected (CDVA) distance visual acuities, manifest refraction stability, slitlamp biomicroscopy, tonometry, and central endothelial cell count (ECC). RESULTS: The study enrolled 42 eyes of 24 patients with a mean age of 35 years (range 18 to 52 years), a mean spherical equivalent of -7.52 D ± 2.22 (SD) (range -2.63 to -13.0 D), and a mean preoperative cylinder of -1.82 ± 0.96 D (range -1.0 to -5.0 D). Six months postoperatively, the UDVA (Snellen lines) was 1.0 or better in 38 eyes (90%). The CDVA improved by 1 line in 22 eyes (52%) and by 2 lines in 2 eyes (5%); no eye lost lines. All eyes were within ±0.50 of the target refraction (spherical equivalent); the mean refractive astigmatism was -0.18 ± 0.30 D. Refraction was stable from 1 day postoperatively. A slight ECC loss (-0.72%) occurred at 6 months. There were no serious complications. CONCLUSION: After a short-time follow-up, toric pIOL implantation was effective, predictable, stable, and safe for the correction of myopic astigmatism.
Authors: Jeihoon Lee; Hun Lee; David Sung Yong Kang; Jin Young Choi; Eung Kweon Kim; Tae Im Kim Journal: Yonsei Med J Date: 2016-11 Impact factor: 2.759
Authors: Soraya M R Jonker; Tos T J M Berendschot; Isabelle E Y Saelens; Noël J C Bauer; Rudy M M A Nuijts Journal: Indian J Ophthalmol Date: 2020-12 Impact factor: 1.848